跳至主要内容
临床试验/NCT00930488
NCT00930488已完成不适用

Treatment of Patients With Acute Sinusitis in Daily Practice

Bayer0 个研究点目标入组 6,777 人开始时间: 2007年3月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
已完成
发起方
Bayer
入组人数
6,777
主要终点
Evaluation of potential benefits of an antibacterial therapy with Avelox® (moxifloxacin) in patients with acute bacterial sinusitis to whom this treatment was prescribed. Especially the time to improvement and resolution of clinical signs and symptoms of

研究概览

简要总结

For each patient, an initial visit and at least one follow-up visit at the end of treatment should be documented by the treating physician in the case report form.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

性别
All
接受健康志愿者

入选标准

  • Any patient with a diagnosis of acute bacterial sinusitis treated with Avelox® - in accordance with the local production information.

排除标准

  • Those specified in the local product information - contraindications and precautions must be considered.

研究组 & 干预措施

Group 1

干预措施: Avelox (Moxifloxacin, BAY12-8039) (Drug)

结局指标

主要结局

Evaluation of potential benefits of an antibacterial therapy with Avelox® (moxifloxacin) in patients with acute bacterial sinusitis to whom this treatment was prescribed. Especially the time to improvement and resolution of clinical signs and symptoms of

时间窗: Documentation at baseline and at at least one follow-up visit. Evaluation of therapy outcome at last follow-up visit at end of therapy (approximately after 7 days).

次要结局

  • Evaluation of tolerability and safety of Avalox® in daily practice were investigated.(Evaluation of therapy outcome at last follow-up visit at end of therapy (approximately after 7 days).)
  • Patient characteristics in acute bacterial sinusitis(Documentation at baseline visit.)
  • History and frequency of sinusitis episodes(Documentation at baseline visit.)
  • Diagnostic procedures and therapeutic options chosen by physicians in daily practice(Documentation at baseline visit.)

研究者

发起方
Bayer
申办方类型
Industry

相似试验